A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT06034002)
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
🩺 Plain-English Summary (8th-Grade Level)
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Who can join: Review the eligibility criteria below.
Location: City of Hope Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- City of Hope Medical Center — Duarte, California
- Stanford Cancer Institute — Palo Alto, California
- University of Miami Health System — Miami, Florida
- The University of Kansas Cancer Center — Westwood, Kansas
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Icahn School of Medicine At Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Vanderbilt University Medical Center — Nashville, Tennessee
- Md Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myeloproliferative Neoplasms
- A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — Herston, Queensland
- Study of INCA036978 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — Chicago, Illinois
- A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms — Phoenix, Arizona
Explore by condition: All Myeloproliferative Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.